Vantage Investment Advisors’s BiondVax Pharmaceuticals Ltd. BVXVW Stock Holding History

Vantage Investment Advisors’s Portfolio BVXVW Stock Details BVXVW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$14K	Hold	12,000	–	–	﹤0.01%	484
2018 Q2	$15K	Hold	12,000	–	–	﹤0.01%	476
2018 Q1	$14K	Hold	12,000	–	–	﹤0.01%	504
2017 Q4	$17K	Hold	12,000	–	–	﹤0.01%	481
2017 Q3	$19K	Hold	12,000	–	–	﹤0.01%	449
2017 Q2	$31K	Hold	12,000	–	–	0.01%	349
2017 Q1	$17K	Hold	12,000	–	–	0.01%	436
2016 Q4	$4K	Hold	12,000	–	–	﹤0.01%	662
2016 Q3	$6K	Buy	+12,000	New	+$6.99K	﹤0.01%	592

Other funds holding BVXVW

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vantage Investment Advisors's BVXVW Position: Q3 2018 in Review

Vantage Investment Advisors held its BiondVax Pharmaceuticals Ltd. (BVXVW) position steady in Q3 2018 at 12,000 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #484.

Vantage Investment Advisors first reported a position in BVXVW in Q3 2016 and has held it in 9 quarters since. The position peaked at $31K in Q2 2017. 4 funds tracked by Wall St. Rank hold BVXVW as of Q3 2018.

Vantage Investment Advisors held 12,000 shares of BiondVax Pharmaceuticals Ltd. worth $14K as of Q3 2018.
Vantage Investment Advisors left its BiondVax Pharmaceuticals Ltd. share count unchanged in Q3 2018.
BiondVax Pharmaceuticals Ltd. made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #484 holding.
Vantage Investment Advisors first reported a position in BiondVax Pharmaceuticals Ltd. in Q3 2016 and has held it in 9 quarters since.
Vantage Investment Advisors's BiondVax Pharmaceuticals Ltd. position peaked at $31K in Q2 2017.
4 funds tracked by Wall St. Rank held BiondVax Pharmaceuticals Ltd. as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.